AKT (also known as Protein Kinase B, PKB) is a serine/threonine kinase that serves as a central node in cellular signaling networks governing cell survival, growth, metabolism, and synaptic plasticity. In neurons, AKT plays critical roles in development, plasticity, and neuroprotection, making it a key molecule in understanding Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. [1]
The AKT family consists of three isoforms (AKT1, AKT2, AKT3) with distinct but overlapping expression patterns in the brain. AKT1 is the most broadly expressed, AKT2 is enriched in metabolic tissues including brain, and AKT3 is highly expressed in neuronal tissue. Each isoform contributes to specific aspects of neural function, and their coordinated activity is essential for normal brain physiology. [2]
AKT signaling is activated by a wide range of extracellular signals, including neurotrophic factors (BDNF, NGF, GDNF), insulin, and cellular stress responses. This central position makes AKT a critical integrator of signals that determine neuronal fate—survival versus death, growth versus atrophy, plasticity versus rigidity.
AKT is activated through a well-characterized PI3K-dependent pathway:
AKT phosphorylates over 100 known substrates, affecting diverse cellular processes including metabolism, protein synthesis, cell cycle regulation, and apoptosis. [3]
| Isoform | Expression Pattern | Specific Functions |
|---|---|---|
| AKT1 | Ubiquitous, highest in cortex and hippocampus | Neuronal survival, synaptic plasticity |
| AKT2 | Moderate, enriched in metabolic neurons | Glucose metabolism, mitochondrial function |
| AKT3 | High in brain, development-critical | Brain development, neuronal morphology |
AKT dysfunction is a hallmark of Alzheimer's disease pathology:
The reduction in AKT signaling contributes to:
Therapeutic Implications: AKT activators and PI3K agonists are being explored as potential AD treatments. However, the complexity of AKT signaling requires careful targeting to avoid adverse effects.
In Parkinson's disease, AKT signaling provides neuroprotection:
Mutations in PINK1 and Parkin impair the protective effects of AKT signaling, making dopaminergic neurons more vulnerable to cellular stress. [5]
AKT dysregulation contributes to motor neuron degeneration in ALS:
Following traumatic brain injury, AKT signaling plays complex roles:
AKT promotes neuronal survival through multiple mechanisms:
AKT is critical for activity-dependent synaptic changes:
AKT integrates neuronal metabolism with survival:
AKT regulates cellular quality control mechanisms:
AKT serves as a key mediator of neurotrophic factor effects:
BDNF activates AKT through TrkB receptor signaling:
NGF signaling through TrkA activates AKT in cholinergic neurons:
GDNF protects dopaminergic neurons through AKT:
Several approaches to activate AKT therapeutically:
Alzheimer's Disease:
Parkinson's Disease:
The discovery of AKT (originally named v-AKT due to its discovery as an oncogene in transforming retrovirus AKT8) dates to the 1970s. Subsequent research revealed its role as a central signaling hub with profound implications for cell biology and disease.
Key milestones in understanding AKT in neurons:
The complexity of AKT signaling, with its multiple isoforms, substrates, and regulatory mechanisms, presents both challenges and opportunities for developing neuroprotective therapies. As our understanding deepens, AKT remains a compelling target for treating neurodegenerative diseases.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brazil DP, et al. AKT signalling in health and disease. Cell. 2019. ↩︎
Datta SR, et al. AKT and neurobiology. Curr Opin Neurobiol. 2017. ↩︎
Manning BD, et al. AKT/PKB signaling: navigating downstream pathways. Nat Rev Drug Discov. 2020. ↩︎
Rosenzweig N, et al. PI3K/AKT pathway in AD pathophysiology. Mol Neurodegener. 2020. ↩︎
Hao R, et al. AKT activation and neuroprotection in PD models. J Neurosci. 2019. ↩︎
Kumar P, et al. AKT in traumatic brain injury mechanisms. Brain. 2020. ↩︎
Zhao X, et al. AKT and synaptic plasticity mechanisms. Brain Res. 2019. ↩︎
Choi JM, et al. Insulin resistance and neurodegeneration connections. Lancet Neurol. 2020. ↩︎
Liu Y, et al. Neurotrophin-mediated AKT activation in neurons. Prog Neuropsychopharmacol Biol Psychiatry. 2020. ↩︎